RxDoctor Payments Data

Michael Thompson

Physician Assistant · New Smyrna Beach, FLNPI 1245570324

Payments from drug & device makers

$398in general payments, 2019–2025

Across 19 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$121
  • Pfizer$65
  • AbbVie$62
  • AstraZeneca$48
  • Eisai Inc.$25
  • Exact Sciences$24
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$121
Pfizer3$65
AbbVie2$62
AstraZeneca3$48
Eisai Inc.1$25
Exact Sciences1$24
Lilly USA, LLC1$19
Amgen1$18
GSK1$15

How this compares

$398 in reported general payments places this provider in the 45th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$84,027
Medicare patients
443
Services billed
1,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$82,519
JardianceEmpagliflozin75$68,698
MounjaroTirzepatide29$31,880
EliquisApixaban25$24,566
JanuviaSitagliptin Phosphate27$19,436
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,119
FarxigaDapagliflozin Propanediol19$11,728
MyrbetriqMirabegron14$9,629
Ipratropium Bromide239$6,557
Megestrol Acetate12$3,581
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,463
Albuterol Sulfate HfaAlbuterol Sulfate76$2,386
Olmesartan Medoxomil122$1,655
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort30$1,636
Rosuvastatin Calcium68$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$121$82,51990 claims
Lilly USA, LLCMounjaro$19$31,88029 claims
PfizerEliquis$65$24,56625 claims
GSKTrelegy Ellipta$15$12,11913 claims
AstraZenecaFarxiga$48$11,72819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in New Smyrna Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →